Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

December 9, 2024

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5 doi:10.58347/tml.2024.1717d

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the 2024-2025 recommendations for treatment and chemoprophylaxis of seasonal influenza.
Compare the antiviral drugs available for treatment of influenza based on their efficacy, dosage and administration, and potential adverse effects.
Determine the most appropriate regimen for influenza treatment or chemoprophylaxis in a particular patient.

Select a term to see related articles antivirals baloxavir FluMist influenza oseltamivir peramivir Rapivab Relenza Tamiflu Xofluza zanamivir

View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.